Application of hibiscus syriacus in preparation of medicine for treating gastric diseases

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of medicine, and particularly relates to an application of a chrysanthemum in the preparation of a medicament for treating gastric diseases (atrophic gastritis, gastric mucosal injury, gastric cancer). BACKGROUND

[0002] Chronic gastritis (CG) is one of the most common diseases worldwide, initially presenting as benign inflammation of the gastric mucosa, similar to oral ulcers. However, if left untreated, it can progress to gastric cancer with a significantly high mortality rate. The development of CG involves multiple stages, including atrophy and reduction of gastric glands, intestinal metaplasia, and heterogeneous hyperplasia within the stomach. First, CSG (simple gastric mucosal injury) can occur in all age groups, and the incidence is age-related; in fact, more than 80% of adults have experienced different degrees of gastric mucosal injury. Currently, CSG uses various drug interventions to alleviate dyspeptic symptoms and treat gastric mucosal inflammation. However, these treatments require long-term drug administration and cause continuous discomfort for patients due to drug intake. Second, the progressive loss of gastric mucosal epithelium is exacerbated with gland atrophy, leading to CAG, which has a globally positive age-related prevalence. Despite this, CAG often exhibits a high recurrence rate and many drug adverse reactions. Furthermore, due to its complex and multifaceted mechanisms, research into chemical drugs for CG has encountered significant challenges. Gastric mucosal injury is the direct cause of CG, so gastric mucosal protection activity is an important evaluation indicator for treating CG.

[0003] Chrysanthemum flowers are the dried flower buds of the chrysanthemum plant, with white color and large flowers being the best. They have a sweet and bitter flavor and a cooling nature, and can clear heat and cool blood, detoxify and reduce swelling, and are used to treat dysentery, leukorrhea, and other symptoms. Chrysanthemum flowers are also an edible flower, and eating them has been recorded in the Book of Songs. Eating them can clear heat, drain dampness, cool blood, and detoxify and beautify the skin.

[0004] There is no mention of "inflammation" in ancient Chinese medical texts, but discussions related to inflammation can be traced back to the term "Yan Shuo" mentioned in the Huangdi Neijing. The Suwen Wuxing Dalun chapter states: "The south produces heat, and heat produces fire … Its change is Yan Shuo." The Shuowen Jiezi states: "Yan, the light of fire, also comes from heavy fire." The Waike Zhengzhi Quanshengji · Cuolu Zonglun records: "Chinese sores and toxins are called inflammation in the West. There are internal and external inflammation." The Chengfang Biandu also states: "Toxicity is the dominance of fire evil." From this, it can be seen that traditional Chinese medicine recognizes inflammation from the aspects of fire, heat, and toxicity. Therefore, chrysanthemum flowers, which clear heat and detoxify, have great prospects in the treatment of inflammation-related diseases.

[0005] In addition, many ancient recipes also have a lot of records about the use of hibiscus flowers. For example, in the "Ji Ji Xian Fang", the red hibiscus flower is dried and ground into powder, and two steamed buns are first cooked and then dipped in the powder for eating, which can treat dysentery and lockjaw; In "Fujian Folk Herbal Medicine", take 9 to 13 hibiscus flowers, add water and ice sugar, and cook for half an hour, then take before meals, twice a day, which can treat hematemesis, hematochezia and dysentery; The "Jianzhen Recipe" can treat stomach upset.

[0006] The traditional application of the above hibiscus flowers shows that hibiscus flowers have been edible since ancient times and have effects on inflammatory diseases, gastrointestinal digestive system discomfort and other symptoms. However, the above symptoms are caused by a wide range of diseases, including various organs such as stomach and intestines in traditional Chinese medicine theory, and have no obvious corresponding relationship with the description of diseases in modern medicine, so they cannot be limited to the gastric diseases such as atrophic gastritis, gastric mucosal damage, precancerous lesions of gastric cancer and other related gastric diseases studied in this patent, and only provide a certain application basis for the research of this patent.

[0007] Based on the status and basis of the prior art, the present application provides an application of hibiscus flowers as a medicine, health care product and food for treating gastric diseases such as atrophic gastritis, gastric mucosal damage, precancerous lesions of gastric cancer and other related gastric diseases. SUMMARY

[0008] The present application aims to provide an application of hibiscus (hibiscus is a plant hibiscus flower and its extract and active monomer) as a medicine, health care product and food for treating gastric diseases (atrophic gastritis, gastric mucosal damage, gastric cancer).

[0009] To achieve the above-mentioned purpose, the technical scheme adopted by the present application is:

[0010] An application of hibiscus in treating gastric diseases.

[0011] The hibiscus is one or several of the flowers of Hibiscus syriacus L. and its variants Hibiscus syriacus f.albusplenus, Hibiscus syriacus f.amplissimus, Hibiscus syriacus f.elegantissimus, Hibiscus syriacus f.grandiflorus, Hibiscus syriacus f.paeoniflorus, Hibiscus syriacus f.totusalbus and Hibiscus syriacus f.violaceus.

[0012] The application of the one or more of the Hibiscus syriacus, Hibiscus syriacus extract, effective part obtained by separation of Hibiscus syriacus extract and single active ingredient in the preparation of drugs for treating stomach diseases and health foods.

[0013] The stomach diseases are one or more of chronic atrophic gastritis, gastric mucosal injury and precancerous lesions.

[0014] The Hibiscus syriacus extract is obtained by extracting dried Hibiscus syriacus flowers with water or an organic solvent; the effective part obtained by separation of the Hibiscus syriacus extract; and the single active ingredient obtained by further preparation and purification of the effective part.

[0015] The organic solvent is one or more of methanol and ethanol.

[0016] The extraction method is one or more of immersion, percolation, decoction, reflux extraction and ultrasonic extraction.

[0017] The preparation and purification method is the preparation and purification of the Hibiscus syriacus extract by extraction and / or macroporous adsorption resin and / or polyamide resin, wherein the extraction uses water and / or an organic reagent, and the organic reagent is one or more of dichloromethane, chloroform, ethyl acetate or n-butanol; and the elution solvent for the macroporous adsorption resin and polyamide preparation and purification is one or more of methanol, ethanol, acetone and a mixed solvent of the foregoing and water.

[0018] The effective part is Hibiscus syriacus flower polyphenol; and the single active compound is compound (I) syringic acid, compound (II) protocatechuic acid, compound (III) kaempferol and compound (IV) kaempferol-7-O-β-D-glucoside.

[0019] Syringic acid (I) belongs to phenylpropanoids, has a molecular formula of C9H 10 O5 and a molecular weight of 198.17 g / mol, and a structural formula of:

[0020]

[0021] Protocatechuic acid (II) belongs to phenylpropanoids, has a molecular formula of C7H6O4, a molecular weight of 154.12 g / mol and a structural formula of:

[0022]

[0023] Kaempferol (III) belongs to flavonoids, has a molecular formula of C 15 H 10 O6, a molecular weight of 286.24 g / mol and a structural formula of:

[0024]

[0025] Kaempferol-7-O-β-D-glucoside (IV) belongs to flavonoid glycosides, molecular formula is C 21 H 20 O 11 , molecular weight is 448.38 g / mol; structural formula is:

[0026]

[0027] Further, the hibiscus extract: dried hibiscus flowers are extracted with 75% ethanol (80 L) at 60°C for 3 times (6.5 kg), each time for 4 hours, and then evaporated to dryness under reduced pressure to obtain the hibiscus flower extract (2.0 kg).

[0028] The hibiscus flower polyphenols are prepared by the following solvent extraction method, macroporous adsorption resin method, and polyamide column chromatography method:

[0029] The solvent extraction method is to suspend the hibiscus flower extract in water, and extract with ethyl acetate to obtain the hibiscus flower polyphenols (25.0 g).

[0030] The macroporous adsorption resin method is to sequentially elute the hibiscus flower extract with water, 30-80% ethanol-water, and 80-95% ethanol-water, and enrich the 30-80% ethanol-water eluate to obtain the hibiscus flower polyphenols (18.6 g). The macroporous resin is a non-polar resin, a weakly polar resin, or a moderately polar resin. The non-polar resin is selected from XAD-4, Diaion HP-20, D101, D102, D401, D1, D2, D3, D4, HPD-100, or X-5. The weakly polar resin is selected from D-201, HPD-300, or AB-8. The moderately polar resin is selected from XAD-6, XAD-7, or XAD-8.

[0031] The polyamide column chromatography method is to sequentially elute the hibiscus flower extract with water, 40% ethanol-water, 60% ethanol-water, and 80% ethanol-water, and enrich the 60-80% ethanol-water eluate to obtain the hibiscus flower polyphenols (12.7 g).

[0032] Further, the monomeric compounds I-IV are obtained by the following method:

[0033] The hibiscus flower polyphenols (25.0 g) are eluted with 75% ethanol by macroporous resin column chromatography, and then gradient eluted with MeOH / H2O (20:80-100:0, v / v) by ODS column chromatography to obtain 4 sub-fractions (Fr. 1, 2.0 g; Fr. 2, 5.2 g; Fr. 3, 5.4 g; Fr. 4, 4.3 g).

[0034] Fr.1 was separated by preparative HPLC (MeOH / H2O, 29:71, v / v; flow rate 8 mL / min) and combined fractions with retention time (10-17; 34-50; 58-68 / min) to obtain three sub-fractions (Fr.1-1, Fr.1-2, Fr.1-3). Fr.1-3 was separated by preparative HPLC (CH3CN / H2O, 13:87, v / v; flow rate 4 mL / min, retention time 30 min) to obtain compound I syringic acid (6.1 mg).

[0035] Fr.3 was separated by preparative HPLC (MeOH / H2O, 55:45, v / v; flow rate 8 mL / min) and combined fractions with retention time (12-21; 26-33; 42-55; 59-71; 82-89; 89-97 / min;) to obtain six sub-fractions (Fr.3-1, Fr.3-2, Fr.3-3, Fr.3-4, Fr.3-5, Fr.3-6). Fr.3-3 was separated by preparative HPLC (CH3CN / H2O, 38:62 v / v; flow rate 3 mL / min, retention time 24 min) to obtain compound II protocatechuic acid (1.7 mg); Fr.3-5 was separated by preparative HPLC (CH3CN / H2O, 42:58 v / v; flow rate 3 mL / min, retention time 20 min) to obtain compound III kaempferol (5.0 mg).

[0036] Fr.2 was separated by preparative HPLC (MeOH / H2O, 40:60, v / v; flow rate 8 mL / min) and combined fractions with retention time (9-14; 21-33; 38-45; 56-69; 80-91; 100-110 / min;) to obtain six sub-fractions (Fr.2-1, Fr.2-2, Fr.2-3, Fr.2-4, Fr.2-5, Fr.2-6). Fr.2-3 was separated by preparative HPLC (CH3CN / H2O, 22:78, v / v; flow rate 3 mL / min, retention time 45 min) to obtain compound IV kaempferol-7-O-β-D-glucoside (109.0 mg).

[0037] A chronic atrophic gastritis medicine containing one or more of hibiscus extract, hibiscus effective part (hibiscus polyphenol), syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-β-D-glucoside (IV).

[0038] Further, the hibiscus extract, effective part, monomer is used as an active ingredient to form a pharmaceutical preparation with a pharmaceutically acceptable carrier, adjuvant or pharmaceutically acceptable excipient.

[0039] The dosage form of the pharmaceutical preparation is a liquid dosage form, a solid dosage form, a semi-solid dosage form, a gaseous dosage form, and an enema, etc.

[0040] The liquid dosage form is a mixture, an oral liquid, a liquor, a tincture, a syrup, an injection, etc.; the solid dosage form is a powder, a granule, a tablet, a capsule, a dripping pill, a film, a suppository, and a pellet; the semi-solid dosage form is an ointment, a paste, a dip, and a licking agent, etc.; and the gaseous dosage form is an aerosol and an inhalant, etc.

[0041] A further object of the present application is to provide the pharmaceutical use of the compound: the prevention and treatment activity evaluation of the chronic gastritis caused by gastric mucosal injury of the active extract of the hibiscus flower. The extract, the effective part and the compound are subjected to in-vitro antioxidant experiment, gastric mucosa protection experiment, cell viability determination and ROS staining, and the in-vitro anti-gastric mucosal injury activity evaluation is carried out with the antioxidant activity and the gastric mucosa protection activity as indexes. The results show that the hibiscus flower extract, the hibiscus flower polyphenol and the monomer compounds I-IV have significant antioxidant activity, and have significant prevention and treatment effects on the chronic gastritis caused by gastric mucosal injury. The compound IV kaempferol-7-O-beta-D-glucoside can reduce the production of ROS, regulate oxidative stress, and protect the gastric mucosa by reducing the apoptosis of GES-1 cells, and has the ability to become a lead compound for treating CG.

[0042] The present application provides the hibiscus flower extract having significant prevention and treatment effects on the chronic gastritis caused by gastric mucosal injury, and the compound having significant protection effect on the gastric mucosa and reducing cell apoptosis without significant cytotoxicity. The hibiscus flower extract, the hibiscus flower polyphenol and the monomer compounds I-IV can be used for preparing a medicine or a lead compound for the chronic gastritis caused by gastric mucosal injury. BRIEF DESCRIPTION OF DRAWINGS

[0043] Figure 1 The hydrogen spectrum of the compound syringic acid (I) in Example 2 of the present application is shown in the following figure:

[0044] Figure 2 The carbon spectrum of the compound syringic acid (I) in Example 2 of the present application is shown in the following figure:

[0045] Figure 3 The hydrogen spectrum of the compound protocatechuic acid (II) in Example 2 of the present application is shown in the following figure:

[0046] Figure 4 The carbon spectrum of the compound protocatechuic acid (II) in Example 2 of the present application is shown in the following figure:

[0047] Figure 5 The hydrogen spectrum of the compound kaempferol (III) in Example 2 of the present application is shown in the following figure:

[0048] Figure 6Carbon spectrum of the compound, kaempferol (III) in Example 2 of the present application;

[0049] Figure 7 Hydrogen spectrum of the compound, kaempferol-7-O-β-D-glucoside (IV) in Example 2 of the present application;

[0050] Figure 8 Cytotoxicity of the hibiscus extract, hibiscus polyphenols and monomeric compounds I-IV against GES-1 in Example 4 of the present application;

[0051] Figure 9 Protective activity of the hibiscus extract, hibiscus polyphenols and monomeric compounds against ethanol-induced GES-1 cells in Example 4 of the present application;

[0052] Figure 10 Effect of the monomeric compound, kaempferol-7-O-β-D-glucoside (IV) on the expression of caspase-3, Bcl-2 and Bax proteins in ethanol-induced GES-1 cells in Example 4 of the present application.

[0053] The application of kaempferol-7-O-β-D-glucoside and hibiscus extract in the preparation of a medicament for treating atrophic gastritis-related gastric diseases is described in detail below through specific examples.

[0054] Example 1 Preparation of hibiscus extract and polyphenols

[0055] The dried hibiscus medicinal material was extracted with 75% ethanol (80 L) at 60°C for 3 times (6.5 kg), each time for 4 hours, and then evaporated to dryness under reduced pressure to obtain the hibiscus extract (2.0 kg).

[0056] The hibiscus extract was suspended in water and extracted with chloroform to obtain the hibiscus polyphenols (12.0 g).

[0057] The hibiscus extract was suspended in water and extracted with dichloromethane to obtain the hibiscus polyphenols (17.0 g).

[0058] The hibiscus extract was suspended in water and extracted with ethyl acetate to obtain the hibiscus polyphenols (25.0 g).

[0059] The hibiscus extract was suspended in water and extracted with n-butanol to obtain the hibiscus polyphenols (189.0 g).

[0060] Example 2 Isolation of polyphenolic compounds from hibiscus

[0061] Hibiscus polysaccharides (25.0 g) were eluted with 75% ethanol using a macroporous resin column, and then subjected to ODS column chromatography using MeOH / H2O (20:80-100:0, v / v) for gradient elution to obtain four sub-fractions (Fr. 1, 2.0 g; Fr. 2, 5.2 g; Fr. 3, 5.4 g; Fr. 4, 4.3 g).

[0062] Fr. 1 was subjected to preparative HPLC (MeOH / H2O, 29:71, v / v; flow rate 8 mL / min) and eluted fractions were combined according to retention time (10-17; 34-50; 58-68 / min) to obtain three sub-fractions (Fr. 1-1, Fr. 1-2, Fr. 1-3). Fr. 1-3 was subjected to preparative HPLC (CH3CN / H2O, 13:87, v / v; flow rate 4 mL / min, retention time 30 min) to obtain compound I syringic acid (6.1 mg).

[0063] Fr. 3 was subjected to preparative HPLC (MeOH / H2O, 55:45, v / v; flow rate 8 mL / min) and eluted fractions were combined according to retention time (12-21; 26-33; 42-55; 59-71; 82-89; 89-97 / min;). Fr. 3-3 was subjected to preparative HPLC (CH3CN / H2O, 38:62 v / v; flow rate 3 mL / min, retention time 24 min) to obtain compound II protocatechuic acid (1.7 mg); Fr. 3-5 was subjected to preparative HPLC (CH3CN / H2O, 42:58 v / v; flow rate 3 mL / min, retention time 20 min) to obtain compound III kaempferol (5.0 mg).

[0064] Fr. 2 was subjected to preparative HPLC (MeOH / H2O, 40:60, v / v; flow rate 8 mL / min) and eluted fractions were combined according to retention time (9-14; 21-33; 38-45; 56-69; 80-91; 100-110 / min;). Fr. 2-3 was subjected to preparative HPLC (CH3CN / H2O, 22:78, v / v; flow rate 3 mL / min, retention time 45 min) to obtain compound IV kaempferol-7-O-β-D-glucoside (109.0 mg).

[0065] High performance liquid chromatography: SHIMADZU SPD-10A (Japan SHIMADZU Corporation); high performance liquid chromatography column: YMC ODS-A (5 μm, 250 x 20 mm) (Japan YMC Corporation); high performance liquid chromatography eluent: methanol (acetonitrile)-water.

[0066] Antioxidant test

[0067] A series of 100 μL aliquots of the test compound (1-200 μg / mL) and ascorbic acid (1-200 μg / mL) were mixed in 96-well plates, respectively. Then, pre-configured ABTS (100 μL) was added to each well. After 30 min of light protection, the absorbance value was measured at 734 nm. Three replicate wells were set in parallel for each group. Methanol was used as a blank control group. The antioxidant degree of the sample was expressed by the ABTS radical inhibition rate, which was calculated by the following formula.

[0068] Inhibition rate (%) = [(Acontrol- Asample) / (Acontrol- Ablank)] x 100%

[0069] DPPH radical scavenging activity was evaluated using the method described previously, with ascorbic acid as a positive control.

[0070] Scavenging capacity was determined by the following formula.

[0071] Inhibition rate (%) = [(Acontrol- Asample) / (Acontrol- Ablank)] x 100% The ferric reducing antioxidant capacity (FRAP) assay was performed according to the method completed. The FRAP working solution was prepared by mixing acetic acid buffer (300 mM, pH 3.6), 10 mM TPTZ (2,4,6-tris(2-pyridyl)-s-triazine) solution (40 mM HCl), and 20 mM ferric trichloride solution (10:1:1). The solution was warmed to 37 °C before use. An aliquot of 100 μL sample was mixed with 100 μL FRAP solution, with an interval of 8 min. After incubation at 37 °C for 4 min, the absorbance was read at 593 nm. The results were expressed as the concentration of standard FeSO4 solution (mmol / L), with ferrous sulfate as a calibration curve.

[0072] Table 1 Antioxidant activity of hibiscus flower extract and kaempferol-7-O-β-D-glucoside

[0073]

[0074] Note: Data are expressed as mean ± SD, n = 3, **** p < 0.0001,*** p<0.001, ** p<0.005, * p<0.05 versus control group.

[0075] The experimental results are shown in Table 1, the hibiscus extract, hibiscus polyphenols and hibiscus monomer compounds I-IV showed free radical scavenging ability and DPPH free radical scavenging ability.

[0076] Example 4 Gastric mucosa protection experiment

[0077] The GES-1 cells were divided into a blank group, a model group and a drug administration group (hibiscus extract group, hibiscus polyphenol group, monomer compound group). Except for the blank group, the rest of the groups were treated with 0.5 mol / L ethanol, and the drug administration group was treated with different concentrations (0-200 μg / ml, 0-200 μM) of drugs in the cell culture solution 6 hours before ethanol treatment, and then the subsequent experiments were performed.

[0078] Cell viability determination: After the GES-1 cells in each group were cultured for 24 hours, 10 μL of CCK-8 solution was added to each well, and incubated at 37°C for 2 hours. The OD value of each well was determined by enzyme labeling method to evaluate the cell viability of the blank group, the model group and the drug administration group.

[0079] Western blot detection: The total protein in the GES-1 cell lysate was extracted according to the RIPA lysis buffer instructions. The protein concentration of each group of cell lysate was determined using a protein concentration determination kit, and the sample buffer was diluted 4 times, mixed uniformly and heated at 100°C for 10 minutes for denaturation, and then cooled for standby. The SDS-PAGE separation gel and concentration gel were prepared according to the PAGE gel ultra-fast preparation kit instructions. Equal amounts (15-25 μg) of protein were loaded into the gel loading well. First, set the voltage to 60V, and when the bromophenol blue enters the lower separation gel, increase the voltage to 120V, and stop the electrophoresis when the bromophenol blue reaches the bottom of the gel. Then wet transfer, set the transfer current to 120mA, and the transfer time is 120 minutes. After the transfer is completed, TBST is rinsed 3 times, the blocking solution is added, and the room temperature is blocked for 2 hours. According to the antibody instructions, incubate the first antibody and the second antibody. After incubation, rinse with TBST 3 times, absorb the washing solution with filter paper, and detect the protein according to the ECL luminescent liquid manufacturer's instructions using a gel imaging instrument.

[0080] As shown in Figure 8 , the hibiscus total extract had no obvious cytotoxicity below 50 μg / mL; the hibiscus polyphenol had no obvious cytotoxicity below 25 μg / mL; and the monomer compounds I-IV had no obvious cytotoxicity below 25 μM.

[0081] As shown in Figure 9As shown, the total extract of hibiscus flower, hibiscus flower polyphenols and monomer compounds I, II, IV, etc. can improve the survival rate of GES-1 cells induced by ethanol, showing good gastric mucosa protective effect. The protective activity of hibiscus flower polyphenols is better than that of hibiscus flower extract. Among the monomer compounds, compound IV kaempferol-7-O-β-D-glucoside has the most significant protective activity on cells, and it is concentration-dependent.

[0082] Meanwhile, Figure 10 The Western blot results in the above table show that after kaempferol-7-O-β-D-glucoside treatment (its L, M, H concentrations are 12.5, 25, 50 μM / ml, respectively), the expressions of Cleaved Caspase-3 and Bax proteins in ethanol-induced GES-1 cells are significantly lower than those in the model group, and the expression of Bcl-2 protein is significantly increased.

[0083] Through the verification of the above four examples, it can be concluded that hibiscus flower extract, hibiscus flower polyphenols and monomer compounds all have good antioxidant activity, and can protect the gastric mucosa by reducing the oxidative stress level of gastric mucosa cells, thereby treating chronic atrophic gastritis.

[0084] Meanwhile, hibiscus flower extract, hibiscus flower polyphenols and monomer compounds can all improve the survival rate of GES-1 cells after ethanol modeling, and have good gastric mucosa protective effect.

[0085] In addition, compound IV kaempferol-7-O-β-D-glucoside can also inhibit apoptosis, improve the symptoms of gastric cancer transformation, precancerous lesions and other symptoms of gastric cancer.

[0086] In summary, hibiscus flower has good application prospect for the treatment of atrophic gastritis related gastric diseases.

Claims

1. Use of Hibiscus in treating stomach diseases.

2. Use according to claim 1, characterized in that: The Hibiscus is one or several of flowers of Hibiscus syriacus L. and its variants, including Hibiscus syriacus f. albusplenus, Hibiscus syriacus f. amplissimus, Hibiscus syriacus f. elegantissimus, Hibiscus syriacus f. grandiflorus, Hibiscus syriacus f. paeoniflorus, Hibiscus syriacus f. totus albus, and Hibiscus syriacus f. violaceus.

3. Use according to claim 1 or 2, characterized in that: The use of one or several of the Hibiscus, Hibiscus extract, effective parts obtained by separation of the Hibiscus extract, and single active ingredients in the preparation of drugs and health products for treating stomach diseases.

4. Use according to claim 3, characterized in that: The stomach diseases are one or several of chronic atrophic gastritis, gastric mucosal damage, and precancerous lesions of the stomach.

5. Use according to claim 3, characterized in that: The Hibiscus extract is obtained by extraction of dried Hibiscus flowers with water or organic solvents; the effective parts obtained by separation of the Hibiscus extract; and the single active ingredients obtained by further preparation and purification of the effective parts.

6. Use according to claim 5, characterized in that: The organic solvents are one or several of methanol and ethanol. The extraction methods are one or several of immersion, percolation, decoction, reflux extraction, and ultrasonic extraction. The preparation and purification methods include extraction and / or macroporous adsorption resin preparation and purification and / or polyamide resin preparation and purification of the Hibiscus extract, wherein the extraction uses water and / or organic reagents, and the organic reagents are one or several of dichloromethane, chloroform, ethyl acetate, or n-butanol; and the elution solvents for macroporous adsorption resin preparation and purification and polyamide preparation and purification are one or several of methanol, ethanol, acetone, and a mixture of the aforementioned substances and water.

7. Use according to claim 5, characterized in that: The effective parts are Hibiscus flower polyphenols; and the single active compounds are syringic acid (I), protocatechuic acid (II), kaempferol (III), and kaempferol-7-O-β-D-glucoside (IV).

8. A drug for chronic atrophic gastritis, characterized by comprising: The drugs and health products contain one or several of Hibiscus flower extract, Hibiscus flower polyphenols, syringic acid (I), protocatechuic acid (II), kaempferol (III), and kaempferol-7-O-β-D-glucoside (IV).

Images